Treatment of Type 2 diabetes with Chiglitazar combined with Metformin Approved for listing by the National Medical Products Administration
SHENZHEN, China, July 19, 2024 /PRNewswire/ -- On July 19, Shenzhen Chipscreen Biosciences Co., Ltd. (hereinafter referred to as "Chipscreen Biosciences") announced that it has received the Drug Registration Certificate approved and issued by the National Medical Products Administration (NMPA) for Chiglitazar, a noval PPAR (Peroxidase Proliferator Activated Receptor) full agonist developed by the company's independently, combined with Metformin...
New Paper Underscores Inflammation’s Role in Atherosclerosis
Understanding the Effect of Inflammation is Key for Early Intervention, Reducing Adverse Cardiovascular Outcomes WASHINGTON, July 19, 2024 /PRNewswire/ -- The International Atherosclerosis Society today released a clinical proceedings white paper outlining the role of inflammation in atherosclerosis and the importance of early intervention. The paper has four main sections: The role of inflammation in atherosclerosis is explained, noting that local...
111 Announces Appointment of New Auditor
SHANGHAI, July 19, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced the appointment of Grant Thornton Zhitong Certified Public Accountants LLP ("Grant Thornton") as the Company's independent registered public accounting...
Rona Therapeutics Raises $35 Million Series A+ Financing to Advance Innovative Metabolic siRNA Pipeline in Clinic and Next Generation RNA Platforms
Financing led by LongRiver Investments with participation by new and existing global investment funds Rona will use proceeds to progress leading metabolic siRNA pipeline programs into global development and expand extra-hepatic delivery platform in CNS and beyond SHANGHAI, July 19, 2024 /PRNewswire/ -- Rona Therapeutics, a clinical stage pioneering platform company in nucleic acid drug research and...
Harbour BioMed Announces Positive Profit Alert for 2024 Interim Results
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, July 19, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology, today announced a positive profit alert for the six months ended June 30, 2024 (the...
VARON Enters CPAP and BiPAP Machine Market with Feature-Rich “Sunny Grand” Series
SEATTLE, July 19, 2024 /PRNewswire/ -- VARON, a leading provider of oxygen concentrator solutions, is thrilled to announce the launch of its new line of CPAP (continuous positive airway pressure) and BiPAP (bilevel positive airway pressure) machines. These machines are designed to deliver effective sleep apnea treatment with maximum comfort and personalized features. This innovative line, known as the SUNNY GRAND...
ACROBiosystems Launches GMP Brand Resilient Supply at ISSCR to Accelerate Cell and Gene Therapy Development
NEWARK, Del., July 19, 2024 /PRNewswire/ -- At the recent International Society for Stem Cell Research (ISSCR) Annual Meeting in Hamburg, ACROBiosystems announced its new GMP-centered brand, Resilient Supply, with the mission of accelerating the advancement of cell and gene therapy (CGT) development. Mike Chen, Chairman, Founder, and CEO of ACROBiosystems Group, was in attendance to introduce the brand....
Ubie and the American Kidney Fund Collaborate to Speed Early Diagnosis and Education for Kidney Disease
Kidney disease kills more Americans every year than breast or prostate cancer, but 9 in 10 don't know they have the disease, leading to late diagnosis and irreversible damage The collaboration will fine tune Ubie's Symptom Checker AI with the goal of accelerating time to diagnosis for patients to improve...
Assessment of supply chain risk key to improving medicine access
A four-year research project by INSEAD and five other institutions sheds light on how understanding medical criticality, supply chain risk and their interactions could help us better address drug shortages. FONTAINEBLEAU, France, SINGAPORE and SAN FRANCISCO, July 18, 2024 /PRNewswire/ -- Drug shortages are becoming an increasing problem in Europe and other parts of the...
DX&VX is on Track and Accelerating the Development of Oral Obesity Treatment
Confirmation of effects compared to global late-stage clinical trials Accelerating the development of obesity treatment through early licensing out, global joint clinical trials, research funding investment, etc. SEOUL, South Korea, July 18, 2024 /PRNewswire/ -- DX&VX, which is gaining attention for developing an oral GLP-1 obesity treatment. The company is accelerating the optimization of new drug candidates....
